Monday, April 28, 2025

Latest

WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

AMD: Analysts Raise Estimates, Markets Shrug Following Earnings

Advanced Micro Devices (NASDAQ: AMD) opened 3% higher but ultimately closed down 1.4% the day...

Friday, April 30, 2021, 03:41:00 PM

Microsoft: Mixed Feelings Following Third Quarter Earnings

Microsoft (NASDAQ: MSFT) opened lower following the release of its financial results earlier this week,...

Saturday, May 1, 2021, 12:57:00 PM

Netflix: Analysts Call For Q2 Revenues Of $8.0 Billion

Netflix (NASDAQ: NFLX) will be reporting its second quarter financial results on July 19 after...

Monday, July 18, 2022, 04:18:00 PM

Stifel: WELL Health Is A “Unique Business Model Still In High Growth Phase”

Earlier this month, WELL Health Technologies (TSX: WELL) reported their second quarter financials, with quarterly...

Sunday, August 23, 2020, 04:05:00 PM

Haywood Drops Cresco Labs Price Target To $24.50

Cresco Labs (CSE: CL) reported its first-quarter financial results this past week. The company announced...

Monday, May 31, 2021, 11:40:00 AM